Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 17/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 16/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 14/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 12/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.53 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.53 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48516 | 0.89 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL27597047 | 0.89 | PIK3CA (0.81) | PIK3CGPIK3CDPIK3CAPIK3CBAOC3 | |
| SCHEMBL48391 | 0.88 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48492 | 0.87 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48569 | 0.86 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48419 | 0.85 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48588 | 0.85 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48825 | 0.84 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48623 | 0.84 | PIK3CD (0.72) | PIK3CGPIK3CDPIK3CAPIK3CBAOC3 | |
| SCHEMBL48734 | 0.83 | PIK3CG (0.80) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| CN-100548996-C | 5-phenylthiazole derivatives and their use for the preparation of medicaments | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | disclosed |
| CN-1639139-A | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CG 8/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CG 8/4885PIK3CD 4/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.